Linagliptin/Μetformin Sandoz

Linagliptin and Metformin Hydrochloride, the active ingredients in Linagliptin/Metformin Sandoz, are a DPP‑4 inhibitor and a biguanide presented as tablets for oral use. They treat type 2 diabetes mellitus in adults, often in combination with diet and exercise.

GNH USA supplies Linagliptin/Metformin Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Linagliptin/Metformin Sandoz is an oral antidiabetic medication used to improve glycaemic control in type 2 diabetes mellitus. - Type 2 diabetes mellitus (monotherapy): provides glucose‑lowering effect when metformin alone is unsuitable. - Type 2 diabetes mellitus (add‑on to metformin): enhances glycaemic control in patients not reaching target with metformin alone. - Type 2 diabetes mellitus (combined with insulin): may allow reduction of insulin dose while maintaining control.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhoea: watery stools, usually transient. - Headache: mild tension‑type headache. - Upper respiratory tract infection: nasopharyngitis symptoms. - Abdominal discomfort: cramping or bloating. - Hypoglycaemia (when combined with sulfonylureas or insulin): sweating, tremor, confusion.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe allergic reactions: rash, angioedema, anaphylaxis. - Acute renal failure: sudden loss of kidney function. - Hepatic failure: jaundice, elevated liver enzymes. - Severe hypoglycaemia: neuroglycopenic symptoms requiring emergency care.

Before initiating therapy, consider the following precautions: - Renal function assessment: evaluate eGFR and avoid use in severe renal impairment. - Hepatic disease: use with caution in patients with liver dysfunction. - Risk of lactic acidosis: contraindicated in conditions predisposing to hypoxia. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. - Drug interactions: review concomitant medications for potential additive effects. - Store at ambient temperature: keep in the original pack, protect from moisture.

Linagliptin/Metformin Sandoz may interact with several medicines. Major Interactions (Avoid): - Sulfonylureas or insulin: increased risk of severe hypoglycaemia. - Iodinated contrast agents: may precipitate renal dysfunction with metformin. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise linagliptin plasma levels. - Renin‑angiotensin system blockers: monitor renal function closely. Moderate Interactions (Monitor Closely): - Beta‑blockers: can mask hypoglycaemia symptoms. - Thiazide diuretics: may attenuate glucose‑lowering effect. - Warfarin: monitor INR as metabolic changes can affect anticoagulation.